Poolbeg Pharma PLC Stock Company Profile
Information
Queen Mary BioEnterprises Innovation Ctr, 42 New Road
London E1 2AX
44 20 7183 1499
www.poolbegpharma.com
Industry: Biotechnology
Sector: Healthcare
![Poolbeg Pharma PLC](/storage/logos/poolbegpharma.com.png)
Description
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.